Angiogenesis and Vascular Heterogeneity

Current anti-angiogenesis therapies (AATs) and traditional immunotherapy suffer resistance and insufficient efficacy in cancer treatment. To overcome these limitations, several characteristics of endothelial cells, such as their heterogeneity and function in immunity, will be studied for their importance in contributing to the partial failure of the above-mentioned therapies. By means of cutting-edge techniques, such as single-cell transcriptomics, this study could potentially lead to the identification of new therapeutic targets whose discovery would improve the efficacy of AAT and could offer opportunities of 'alternative immunotherapy'.